Neurogene Inc. 8-K

What Happened
Neurogene Inc. announced on February 26, 2026 (Form 8‑K, Item 7.01) that NGN-401, the company’s investigational gene therapy in late‑stage clinical development for the treatment of Rett syndrome, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company issued a press release about the designation (attached as Exhibit 99.1 to the Form 8‑K). The filing was signed by Christine Mikail, President and Chief Financial Officer.

Key Details

• Breakthrough Therapy Designation granted by the FDA for NGN-401 (announced Feb 26, 2026).
• NGN-401 is described as an investigational gene therapy in late‑stage clinical development for Rett syndrome.
• Disclosure made via Form 8‑K under Item 7.01 (Regulation FD Disclosure); press release attached as Exhibit 99.1.
• Form 8‑K signed by Christine Mikail (President, CFO).

Why It Matters
Breakthrough Therapy Designation is a regulatory recognition that can speed development and review by enabling more intensive FDA guidance and potential priority review pathways. For investors, the designation is a milestone that may increase the program’s regulatory visibility and could affect development timelines and the company’s clinical strategy. This 8‑K reports the designation itself but does not provide new financial results or additional operational details.